Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms

Song, Youngseok; Lim, Jean K.; Lim, Tze-Peng; Im, Keon-Il; Kim, N.; Nam, Yoonho; Jeon, Young‐Woo; Ko, Hyun Sun; Park, I.; Shin, Jong‐Hee; Cho, S.

doi:10.1016/s1465324921003455

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…153 Direct analysis of the immunosuppressive effects of BMand UC-MSCs has revealed that these cells exert similar inhibitory effects in vitro with different mechanisms involved. 157 With these conflicting data, the mechanism of action related to the immune response of MSCs from different sources is still poorly understood, and long-term investigations both in preclinical studies and in clinical trial settings are needed to shed light on this complex immunomodulation function.…”

Section: An Overview Of Msc Tissue Origins and Therapeutic Potentialmentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

405

138

View full text Add to dashboard Cite

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

show abstract

Section: An Overview Of Msc Tissue Origins and Therapeutic Potentialmentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

405

138

View full text Add to dashboard Cite

show abstract

“…It is considered that to be cell contact dependent or independent (21)(22)(23). MSCs also can inhibit different immune cells such as DC, monocytes, and NK (24)(25)(26)(27)(28).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Relationship Between Mesenchymal Stem Cells and Immune System In vitro Conditions

Erol

Sel

Süleymanoğlu

et al. 2022

Preprint

View full text Add to dashboard Cite

Determination of the immunomodulatory properties of mesenchymal stem cells (MSCs) is necessary before clinical applications. In this study, it was aimed to determine the effect of MSCs on cytokines secreted by the immune system cells. Intracellular cytokine levels (Interleukin-4 (IL-4), Interferon-γ (IFN-γ), and Interleukin-17 (IL-17)) detected by flow cytometry before and after co-culture between peripheral blood mononuclear cells (PBMCs) and MCSs. At the same time, supernatant cytokine levels were measured using the ELISA. In our study, MSCs were isolated from cord blood (CB) and Wharton’s Jelly (WJ), and their surface markers (CD44 (100%), CD73 (99.6%), CD90 (100%), CD105 ( 88%)) shown by flow cytometry method. Both CB-MSCs and WJ-MSCs were used in co-culture MSC/PBMC ratios of 1/5 and 1/10, incubation times of 24 hours and 72 hours. In the present study, when we compared co-cultures of CB-MSC or WJ-MSC with PBMCs, intracellular levels of cytokines IFN-γ, IL-17 (pro-inflamatory) and IL-4 (anti-inflamatory) were increased and supernatant levels were decreased significantly (p < 0.05). The level of TGF-β (anti-inflamatory) was significantly decreased for both CB-MSC and WJ-MSC in supernatant (p < 0.05). It was investigated the pro-inflammatory and anti-inflammatory effects of CB-MSCs and WJ-MSCs on PBMCs with the obtained results. According to the results, MSCs demonstrated different immunologic effects after the incubation time and ratios For further studies, it should be known between interaction of MSCs and immune system.

show abstract

Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms

Cited by 2 publications

References 0 publications

Stem cell-based therapy for human diseases

Stem cell-based therapy for human diseases

Evaluation of the Relationship Between Mesenchymal Stem Cells and Immune System In vitro Conditions

Contact Info

Product

Resources

About